- Home
- NXTC vs EDSA Comparison
NXTC vs EDSA Comparison
Compare NXTC & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- EDSA
- Stock Information
- Founded
- NXTC 2015
- EDSA 2015
- Country
- NXTC United States
- EDSA Canada
- Employees
- NXTC N/A
- EDSA N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- EDSA Health Care
- Exchange
- NXTC Nasdaq
- EDSA Nasdaq
- Market Cap
- NXTC 12.8M
- EDSA 15.4M
- IPO Year
- NXTC 2019
- EDSA N/A
- Fundamental
- Price
- NXTC $5.12
- EDSA $2.24
- Analyst Decision
- NXTC Strong Buy
- EDSA Strong Buy
- Analyst Count
- NXTC 2
- EDSA 2
- Target Price
- NXTC $25.50
- EDSA $13.00
- AVG Volume (30 Days)
- NXTC 318.4K
- EDSA 21.9K
- Earning Date
- NXTC 08-07-2025
- EDSA 08-08-2025
- Dividend Yield
- NXTC N/A
- EDSA N/A
- EPS Growth
- NXTC N/A
- EDSA N/A
- EPS
- NXTC N/A
- EDSA N/A
- Revenue
- NXTC N/A
- EDSA N/A
- Revenue This Year
- NXTC N/A
- EDSA N/A
- Revenue Next Year
- NXTC N/A
- EDSA N/A
- P/E Ratio
- NXTC N/A
- EDSA N/A
- Revenue Growth
- NXTC N/A
- EDSA N/A
- 52 Week Low
- NXTC $2.69
- EDSA $1.55
- 52 Week High
- NXTC $19.80
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- NXTC 48.99
- EDSA 52.38
- Support Level
- NXTC $4.75
- EDSA $2.02
- Resistance Level
- NXTC $5.23
- EDSA $2.28
- Average True Range (ATR)
- NXTC 0.31
- EDSA 0.13
- MACD
- NXTC 0.02
- EDSA -0.01
- Stochastic Oscillator
- NXTC 53.28
- EDSA 59.72
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.